ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2713

A Novel Paradigm in the Clinical Context of Rheumatoid Arthritis: Role of Tfh and Th17 Cells in Autoimmunity

Magdalena Budziakowska1, Arif Shahzad1, Jerry Pounds1, Shikha Singla1, Jerald M. Zakem1,2, Kismet Collins1, Tamika Webb-Detiege1, William E. Davis1,2, Zongbing You3, Robert Quinet1,2 and Xin Zhang4, 1Rheumatology, Ochsner Medical Center, New Orleans, LA, 2University of Queensland School of Medicine, Brisbane, Australia, 3Tulane University Health Science Center, New Orleans, LA, 4Laboratory of Cellular Immunology, Institution of Translational Research, Ochsner Medical Center, New Orleans, LA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Auto-immunity, autoantibodies, pathogenesis and rheumatoid arthritis (RA), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of synovium, which causes progressive joint destruction and reduction in quality of life for patients. The Th1/Th2 paradigm is a model for the induction and regulation of immune responses. Th1 cells participate in cell-mediated immunity whereas Th2 cells support humoral immunity. Recently, Tfh and Th17 cells have emerged as the novel T cell subsets controlling autoimmunity. Identifying their roles may break the Th1/Th2 axis dichotomy, bridge the knowledge gap of T cell lineages on RA immunopathogenesis, and lead to novel therapeutic approaches for RA patients. We examined the frequency of Tfh and Th17 cells in RA patients, and investigated their correlation with disease activity, autoantibody levels, and inflammation. 

Methods:

Peripheral blood was collected from 51 RA patients meeting 2010 ACR/EULAR RA classification criteria and 51 age-/gender-matched healthy donors. Clinical disease activity was quantified using the Disease Activity Score in 28 joints (DAS-28). RA patients were divided into remission (DAS-28<2.6) and active disease groups (DAS-28>2.6) based on their DAS-28. Serum laboratory measurements including Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide antibody (anti-CCP), Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were obtained. The frequency of Tfh cells (CD4+CXCR5+ICOS+ PD-1+) and Th17 cells (CD4+CCR4+CCR6+) were measured by flow cytometry and analyzed by sequential gating. The plasmablasts (CD20loCD38+CD138–) in the peripheral blood were measured by flow cytometry. Correlation of the frequency of circulating Tfh cells and Th17 cells with DAS-28, plasmablasts, and laboratory parameters were statistically determined. 

Results:

Both circulating Tfh cells (CD4+CXCR5+ICOS+ PD-1+) and Th17 cells (CD4+CCR4+CCR6+) were significantly increased in RA patients, expecially in moderate/severe patients (p<0.05), comparing to healthy donors. The frequency of circulating Tfh cells correlated with the percentage of plasmablasts and the level of pathogenic anti-CCP antibody, whereas the frequency of circulating Th17 cells correlated with the serum level of RF and CRP as well as DAS-28. 

Conclusion:

Our data suggests that Tfh and Th17 cells may play different roles in RA pathogenesis. Tfh cells may contribute to B cell differentiation and autoantibody production,  while Th17 cells may be involved in the inflamation and pathogenesis of RA. Thus, disrupting the signals provided by Tfh and Th17 cells may offer new therapeutic stategies for severe RA patients and shift their immune system toward homeostasis.


Disclosure: M. Budziakowska, None; A. Shahzad, None; J. Pounds, None; S. Singla, None; J. M. Zakem, None; K. Collins, None; T. Webb-Detiege, None; W. E. Davis, None; Z. You, None; R. Quinet, None; X. Zhang, None.

To cite this abstract in AMA style:

Budziakowska M, Shahzad A, Pounds J, Singla S, Zakem JM, Collins K, Webb-Detiege T, Davis WE, You Z, Quinet R, Zhang X. A Novel Paradigm in the Clinical Context of Rheumatoid Arthritis: Role of Tfh and Th17 Cells in Autoimmunity [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/a-novel-paradigm-in-the-clinical-context-of-rheumatoid-arthritis-role-of-tfh-and-th17-cells-in-autoimmunity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-paradigm-in-the-clinical-context-of-rheumatoid-arthritis-role-of-tfh-and-th17-cells-in-autoimmunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology